adult patients with primary hyperlipidemia and mixed dyslipidemia as an adjunct to diet to reduce elevated total-C, LDL-C, ApoB, non HDL-C, and TG levels and to increase HDL-C
adult patients with hypertriglyceridemia as an adjunct to diet
adult patients with primary dysbetalipoproteinemia (Type III hyperlipoproteinemia) as an adjunct to diet
adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C, total-C, and ApoB
slowing the progression of atherosclerosis as part of a treatment strategy to lower total-C and LDL-C as an adjunct to diet
risk reduction of MI, stroke, and arterial revascularization procedures in patients without clinically evident CHD, but with multiple risk factors
How it works
Rosuvastatin is a selective and competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme that converts HMG-CoA to mevalonate, a precursor of cholesterol. It increases the number of hepatic low-density lipoprotein (LDL) receptors on the cell-surface to enhance uptake and catabolism of LDL. Also, rosuvastatin inhibits hepatic synthesis of very-low-density lipoprotein (VLDL), which reduces the total number of VLDL and LDL particles.
Indications
adult patients with primary hyperlipidemia and mixed dyslipidemia as an adjunct to diet to reduce elevated total-C, LDL-C, ApoB, non HDL-C, and TG levels and to increase HDL-C
adult patients with hypertriglyceridemia as an adjunct to diet
adult patients with primary dysbetalipoproteinemia (Type III hyperlipoproteinemia) as an adjunct to diet
adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C, total-C, and ApoB
slowing the progression of atherosclerosis as part of a treatment strategy to lower total-C and LDL-C as an adjunct to diet
risk reduction of MI, stroke, and arterial revascularization procedures in patients without clinically evident CHD, but with multiple risk factors
Dosage
5-40 mg once daily. Use 40 mg dose only for patients not reaching LDL-C goal with 20 mg.
Side Effects
Muscle pain, Joint pain, Diabetes mellitus, Sore throat, Headache, Weakness, Lack of energy, Dizziness, Creatine phosphokinase increased, Nausea, Abdominal pain, Constipation, Urinary tract infection, Hypersensitivity, Rash, Itching, Hives, Swelling, Pancreatitis
Contraindication
Rosuvastatin is contraindicated in the following conditions:
Patients with a known hypersensitivity to any component of this product. Hypersensitivity reactions including rash, pruritus, urticaria, and angioedema have been reported with Rosuvastatin.
Patients with active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels
Pregnancy
Lactation: Limited data indicate that Rosuvastatin is present in human milk. Because statins have the potential for serious adverse reactions in nursing infants, women who require Rosuvastatin treatment should not breastfeed their infants